<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NEDOCROMIL SODIUM</span><br/>(ned'o-cro-mil)<br/><span class="topboxtradename">Tilade, </span><span class="topboxtradename">Alocril<br/></span><b>Classifications:</b> <span class="classification">antiinflammatory</span>; <span class="classification">mast cell stabilizer</span>; <span class="classification">antiasthmatic</span><br/><b>Prototype: </b>Cromolyn sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1.75 mg aerosol; 2% ophthalmic solution</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits activation of and mediators released from inflammatory cell types associated with asthma (e.g., neutrophils, mast
         cells, monocytes).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits release of inflammatory mediators including histamine and prostaglandin D<sub>2</sub>. Has no intrinsic bronchodilator, antihistamine, or glucocorticoid effects.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Maintenance therapy for patients with mild to moderate asthma. Ocular use for allergic conjunctivitis (see Appendix A-1).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to nedocromil; acute bronchospasm, particularly status asthmaticus.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B), lactation. Safety and effectiveness in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Asthma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Inhalation</span> 2 inhalations q.i.d. at regular intervals, <b><small>NOT</small></b> for acute asthma attacks<br/><span class="rdage">Child:</span> <span class="rdroute">Inhalation</span> <img src="../images/special/lesserorequal.gif"/><i>6 y,</i> 2 inhalations q.i.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Inhalation</span><br/><ul>
<li>Use correct administration technique to ensure maximum drug efficacy. Review instruction leaflet supplied by manufacturer.</li>
<li>Reduce dosage in stages, with each lower dose maintained for several weeks of good control prior to further decreasing dose.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> <span class="speceff-common">Abnormal bitter taste,</span> nausea, vomiting. <span class="typehead">CNS:</span> Headache, dizziness. <span class="typehead">Respiratory:</span> Sore throat irritation, cough. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 90% of dose is deposited in throat and swallowed. Less than 7% is absorbed systemically in patients with asthma. <span class="typehead">Onset:</span> 1 wk for therapeutic effect. <span class="typehead">Peak:</span> 10Â–20 min. <span class="typehead">Metabolism:</span> Does not appear to be metabolized. <span class="typehead">Elimination:</span> 6% excreted in urine in 72 h. <span class="typehead">Half-Life:</span> 2.3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess for coughing and bronchospasms induced by nedocromil. These are indications for discontinuation of drug and should
            be promptly reported.
         </li>
<li>Monitor patients for whom systemic or inhaled steroid therapy has been reduced, as nedocromil may not fully substitute for
            the decrease in dose of steroid.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn to administer the drug properly. Review patient instruction leaflet.</li>
<li>Do not use it to treat acute bronchospasms because nedocromil is not a bronchodilator.</li>
<li>Continue regular nedocromil therapy even during symptom-free periods.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>